Total Payments
$7,769
2024 Payments
$335.07
Companies
33
Transactions
450
Medicare Patients
1,854
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$5,729 (73.7%)
Consulting$1,462 (18.8%)
Travel$411.76 (5.3%)
Education$165.70 (2.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,729 | 441 | 73.7% |
| Consulting Fee | $1,462 | 1 | 18.8% |
| Travel and Lodging | $411.76 | 5 | 5.3% |
| Education | $165.70 | 3 | 2.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Cardinal Health 108, LLC | $1,938 | 7 | $0 (2017) |
| Amgen Inc. | $1,271 | 94 | $0 (2024) |
| PFIZER INC. | $835.00 | 65 | $0 (2024) |
| Janssen Biotech, Inc. | $565.49 | 42 | $0 (2024) |
| Genentech USA, Inc. | $459.91 | 36 | $0 (2024) |
| ABBVIE INC. | $451.16 | 31 | $0 (2024) |
| Lilly USA, LLC | $391.25 | 34 | $0 (2021) |
| GlaxoSmithKline, LLC. | $295.00 | 22 | $0 (2023) |
| UCB, Inc. | $267.09 | 21 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $251.93 | 21 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $335.07 | 22 | ABBVIE INC. ($162.85) |
| 2023 | $478.82 | 33 | Amgen Inc. ($166.73) |
| 2022 | $705.13 | 50 | Amgen Inc. ($222.38) |
| 2021 | $531.42 | 39 | Amgen Inc. ($191.77) |
| 2020 | $424.39 | 31 | Lilly USA, LLC ($65.77) |
| 2019 | $1,052 | 81 | Amgen Inc. ($179.87) |
| 2018 | $1,119 | 96 | PFIZER INC. ($199.18) |
| 2017 | $3,123 | 98 | Cardinal Health 108, LLC ($1,938) |
All Payment Transactions
450 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | PFIZER INC. | XELJANZ (Drug) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 12/16/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.91 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: IMMUNOLOGY | ||||||
| 11/19/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $14.48 | General |
| Category: Bone Health | ||||||
| 10/28/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 10/22/2024 | Genentech USA, Inc. | Actemra (Biological) | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: Immunology | ||||||
| 09/18/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $13.77 | General |
| Category: IMMUNOLOGY | ||||||
| 09/09/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $14.32 | General |
| Category: Bone Health | ||||||
| 09/04/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 08/28/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $16.66 | General |
| Category: IMMUNOLOGY | ||||||
| 08/12/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: Immunology | ||||||
| 06/25/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $15.85 | General |
| Category: Immunology | ||||||
| 06/12/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: Bone Health | ||||||
| 06/10/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.97 | General |
| Category: IMMUNOLOGY | ||||||
| 05/15/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $11.68 | General |
| Category: IMMUNOLOGY | ||||||
| 04/24/2024 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: Inflammation | ||||||
| 04/02/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: IMMUNOLOGY | ||||||
| 03/13/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $12.56 | General |
| Category: IMMUNOLOGY | ||||||
| 02/21/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: IMMUNOLOGY | ||||||
| 02/21/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $13.42 | General |
| Category: Bone Health | ||||||
| 01/10/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: IMMUNOLOGY | ||||||
| 01/02/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: IMMUNOLOGY | ||||||
| 12/13/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: IMMUNOLOGY | ||||||
| 12/12/2023 | Amgen Inc. | Enbrel (Biological) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: Inflammation | ||||||
| 12/06/2023 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $16.26 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 459 | 8,826 | $498,945 | $280,193 |
| 2022 | 13 | 472 | 8,676 | $660,260 | $278,691 |
| 2021 | 13 | 440 | 7,911 | $757,700 | $293,315 |
| 2020 | 13 | 483 | 8,439 | $857,020 | $329,857 |
Total Patients
1,854
Total Services
33,852
Medicare Billing
$1.2M
Procedure Codes
51
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 13 | 4,050 | $202,500 | $107,004 | 52.8% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 34 | 3,180 | $82,440 | $58,755 | 71.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 156 | 556 | $94,520 | $55,781 | 59.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 27 | 207 | $43,470 | $23,244 | 53.5% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 43 | 179 | $17,900 | $11,499 | 64.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 38 | 48 | $12,000 | $7,133 | 59.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 42 | 71 | $8,875 | $5,199 | 58.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 27 | 27 | $7,425 | $4,574 | 61.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 16 | 189 | $23,625 | $4,543 | 19.2% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 16 | 27 | $2,885 | $1,534 | 53.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 12 | 12 | $1,920 | $693.24 | 36.1% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 35 | 280 | $1,385 | $233.89 | 16.9% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2022 | 12 | 3,980 | $347,000 | $113,129 | 32.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 167 | 542 | $110,995 | $56,065 | 50.5% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 30 | 3,180 | $79,500 | $54,780 | 68.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 29 | 181 | $44,090 | $21,274 | 48.3% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 34 | 128 | $12,800 | $8,789 | 68.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 57 | 97 | $13,975 | $6,451 | 46.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2022 | 14 | 192 | $24,000 | $4,995 | 20.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 26 | 26 | $7,375 | $4,770 | 64.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 21 | 25 | $7,060 | $3,856 | 54.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 15 | 38 | $8,060 | $2,371 | 29.4% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 13 | 20 | $2,000 | $1,157 | 57.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 26 | 69 | $2,415 | $878.55 | 36.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 28 | 198 | $990.00 | $176.15 | 17.8% |
About Dr. Mark Fisher, MD
Dr. Mark Fisher, MD is a Rheumatology healthcare provider based in Haddon Heights, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609961937.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Fisher, MD has received a total of $7,769 in payments from pharmaceutical and medical device companies, with $335.07 received in 2024. These payments were reported across 450 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($5,729).
As a Medicare-enrolled provider, Fisher has provided services to 1,854 Medicare beneficiaries, totaling 33,852 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Ad
Practice Information
- Specialty Rheumatology
- Location Haddon Heights, NJ
- Active Since 10/03/2006
- Last Updated 06/18/2010
- Taxonomy Code 207RR0500X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1609961937
Products in Payments
- Enbrel (Biological) $945.75
- XELJANZ (Drug) $734.92
- Rituxan (Biological) $432.63
- RINVOQ (Biological) $358.81
- TALTZ (Drug) $299.38
- BENLYSTA (Biological) $282.10
- Cimzia (Drug) $267.09
- EVENITY (Biological) $267.06
- COSENTYX (Biological) $251.93
- SIMPONI ARIA (Biological) $226.85
- ACTHAR (Biological) $187.42
- TREMFYA (Drug) $183.71
- INFLECTRA (Biological) $115.08
- REMICADE (Biological) $107.78
- ORENCIA (Biological) $96.57
- FORTEO (Drug) $79.89
- RENFLEXIS (Biological) $76.74
- KRYSTEXXA (Biological) $70.68
- SAPHNELO (Biological) $65.37
- KEVZARA (Drug) $63.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.